December 17, 2012
Shareholders of Lexicon (NASDAQ: LXRX ) have been on a real roller-coaster ride with this stock, as the company at one point saw its drug LX2931 beaten by an incredible placebo that reduced patient symptoms by 49%, outperforming the drug itself at 44%. Now, however, the company's drug LX1033 has a chance to make up lost ground, as it has just received a fast-track designation from the FDA in its indication to treat irritable bowel syndrome. In this video, Motley Fool health care analyst David Williamson tells us whether this is going to be a major needle-mover for Lexicon and if there are other factors to watch with this company.
In the world of health care, companies simply don't come any bigger than Johnson & Johnson. Many own the stock, but few understand its story. Offering everything from baby powder to biologics, critics think the company has spread itself too thin, becoming nothing more than a bloated corporate whale. Is this true, or is J&J a well-diversified giant that's perfect for your portfolio? Make sure you understand the full story behind the stock, along with its key opportunities and risks, by checking out our brand new premium report on Johnson & Johnson. To claim your copy simply click here now for instant access.